FREE FOR EVERYONE
Solid tumors represent approximately 90% of all cancers. Chimeric antigen receptor T (CAR-T) cells have shown promising outcomes in the treatment of hematologic malignancies. However, CAR-T cell therapy in solid tumor treatment has been significantly hindered, due to the complex tumor microenvironment (TME) in solid tumors affects the proliferation and infiltration of CAR-T cells, namely two of the barriers limiting the lack of tumor-specific targets and poor tumor infiltration. We believe we can overcome these barriers by using our proprietary E-ALPHA (Eureka Adaptive Library Panning for Human Antibodies) and ARTEMIS(Antibody Redirected T Cells with Endogenous Modular Immune Signaling) platforms. We have developed E-ALPHA into one of the world’s largest human-derived antibody phage libraries to generate target-specific antibodies, including T cell receptor (TCR)-mimic antibodies against intracellular targets. In addition, we have developed our ARTEMIS Cell Receptor Platform to incorporate the activation pathways of a TCR with proprietary technology to infiltrate solid tumors. This presentation will introduce. 1 Showcasing a novel T cell platform: “ARTEMIS vs CAR Technology” in T-cell therapy against solid tumors. 2 Targeting Glypican 3 (GPC3) in advanced hepatocellular carcinoma (HCC).3 Designing ARTEMIS Antibody TCR (AbTCR) T cells to address the major hurdles in treating solid tumor. 4 Infiltrating into solid tumor under immunosuppressive microenvironment. 5 Demonstrating superior safety and efficacy profile of ARTEMIS T cells.
Sign in to Register
